246 related articles for article (PubMed ID: 11433064)
1. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
[TBL] [Abstract][Full Text] [Related]
2. An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine.
Schoen RT; Deshefy-Longhi T; Van-Hoecke C; Buscarino C; Fikrig E
Clin Ther; 2003 Jan; 25(1):210-24. PubMed ID: 12637121
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.
Feder HM; Beran J; Van Hoecke C; Abraham B; De Clercq N; Buscarino C; Parenti DL
J Pediatr; 1999 Nov; 135(5):575-9. PubMed ID: 10547245
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.
Schoen RT; Sikand VK; Caldwell MC; Van Hoecke C; Gillet M; Buscarino C; Parenti DL
Clin Ther; 2000 Mar; 22(3):315-25. PubMed ID: 10963286
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
Zhao H; Bao FF; Liu A
J Infect Dev Ctries; 2017 Jan; 11(1):1-9. PubMed ID: 28141584
[TBL] [Abstract][Full Text] [Related]
7. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
Wressnigg N; Barrett PN; Pöllabauer EM; O'Rourke M; Portsmouth D; Schwendinger MG; Crowe BA; Livey I; Dvorak T; Schmitt B; Zeitlinger M; Kollaritsch H; Esen M; Kremsner PG; Jelinek T; Aschoff R; Weisser R; Naudts IF; Aichinger G
Clin Vaccine Immunol; 2014 Nov; 21(11):1490-9. PubMed ID: 25185574
[TBL] [Abstract][Full Text] [Related]
8. Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.
Onrust SV; Goa KL
Drugs; 2000 Feb; 59(2):281-99. PubMed ID: 10730551
[TBL] [Abstract][Full Text] [Related]
9. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
10. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
[TBL] [Abstract][Full Text] [Related]
11. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.
Sigal LH; Zahradnik JM; Lavin P; Patella SJ; Bryant G; Haselby R; Hilton E; Kunkel M; Adler-Klein D; Doherty T; Evans J; Molloy PJ; Seidner AL; Sabetta JR; Simon HJ; Klempner MS; Mays J; Marks D; Malawista SE
N Engl J Med; 1998 Jul; 339(4):216-22. PubMed ID: 9673299
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.
Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S
Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults.
Van Hoecke C; Comberbach M; De Grave D; Desmons P; Fu D; Hauser P; Lebacq E; Lobet Y; Voet P
Vaccine; 1996 Dec; 14(17-18):1620-6. PubMed ID: 9032890
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine.
Keller D; Koster FT; Marks DH; Hosbach P; Erdile LF; Mays JP
JAMA; 1994 Jun; 271(22):1764-8. PubMed ID: 8196120
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease.
Schoen RT; Meurice F; Brunet CM; Cretella S; Krause DS; Craft JE; Fikrig E
J Infect Dis; 1995 Nov; 172(5):1324-9. PubMed ID: 7594671
[TBL] [Abstract][Full Text] [Related]
16. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
17. Availability of Lyme disease vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Jan; 48(2):35-6, 43. PubMed ID: 9933128
[TBL] [Abstract][Full Text] [Related]
18. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine.
Van Hoecke C; Lebacq E; Beran J; Parenti D
Clin Infect Dis; 1999 Jun; 28(6):1260-4. PubMed ID: 10451163
[TBL] [Abstract][Full Text] [Related]
19. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
20. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
